A PDE4B Inhibitor With Demonstrated Clinical Potential in Treating IPF
nerandomilast (BI 1015550)
PDE4B inhibitor Ph. III in idiopathic pulmonary fibrosis, interstitial lung diseases hit identification method undisclosed Br. J. Pharmacol., August 2024 Boehringer Ingelheim, Biberach, DE
Other molecules you may be interested in
obicetrapib
Context. Obicetrapib (Monash University and NewAmsterdam Pharma) is an oral selective cholesteryl ester transfer protein (CETP) inhibitor being developed for dyslipidemia. Patients with high cardiovascular risk typically aim to lower cholesterol with a combination of statins, diet, and exercise, but this is often not enough . A foundational [...]
PF-07328948
Pfizer disclosed the structure and discovery of their oral small molecule BDK inhibitor/degrader, PF-07328948, during the ACS Fall 2024 First-Time Disclosures session in Denver. The team identified a thiophene carboxylic acid-based hit targeting an allosteric pocket on BDK. Through optimization, they overcame challenges such as potential IADRs and BDK-E2 complex stabilization. By manipulating the dihedral angle of the methoxy group, they enhanced binding interactions, verifying PF-07328948's unexpected mechanism of action in vivo. PF-07328948 is currently Ph. I trials.
"compound 12" (GlaxoSmithKline)
“compound 12” is a selective inhibitor of integrin αvβ5, a potential target for sepsis due to its potential role in regulating vascular leakage. Selectivity among integrin family members can be challenging to achieve and can have significant safety implications – hence, most integrin drugs have been selective biologics. Since the biological [...]
milvexian
The BMS factor XIa inhibitor, milvexian (BMS-986177), is an oral antithrombotic with a Ki of 0.11 nM. A member of this macrocyclic series was previously highlighted as one of 2020’s Molecules of the Year . Poor pharmaceutic properties from previous preclinical molecules such as solubility were addressed resulting in this candidate. Milvexian [...]
